What the HHS Peptide Policy Actually Says, and What It Doesn't
On October 28, 2026, HHS issued an enforcement discretion policy covering six peptides. The Federal Register published it on October 30 (Doc. 2026-22192, Docket HHS-OASH-2026-0496). Comments are open for two weeks after publication, through approximately November 13, 2026 (two weeks after publication).
Here is what the primary document says — not what coverage says about it.
The Six Peptides
- BPC-157 acetate
- TB-500 acetate (thymosin beta-4)
- KPV acetate
- MOTS-c acetate
- Semax free base
- Epitalon acetate
What the Policy Is
HHS will not take enforcement action against state-licensed 503A pharmacies, federal facilities, or licensed physicians who compound these six peptides — under specific conditions. This is enforcement discretion. The law did not change.
What the Policy Is Not
The notice states that the interim policy is not binding on HHS or the public and does not establish legal rights.
It is not FDA approval. It does not add the compounds to the official 503A Bulks List. It can be withdrawn without rulemaking.
The Conditions
HHS will exercise enforcement discretion only when all of these are met:
- The peptide is listed in the policy's appendix, in the stated form and route
- Single active ingredient only: combination products are excluded
- Bulk substance from an FDA-registered facility, with a valid certificate of analysis
- Original bulk manufacturer FDA-registered and CGMP-compliant: a repacker's registration does not substitute
- Serious adverse events reported to FDA's MedWatch program
- Mandated label: "This is a compounded drug product. Not for resale."
- Oral formulations: documentation that the formulation is adequately bioavailable in humans
- Device: the only co-packaged delivery device is an FDA 510(k)-cleared syringe
- Compliance with all other applicable FD&C Act provisions
Section 503A compounding is prescription-based: it applies to compounding for an identified patient on a prescription from a licensed prescriber.
Per-Peptide Route Restrictions
| Peptide | Allowed routes |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical |
| TB-500 acetate | Subcutaneous or intramuscular only |
| MOTS-c acetate | Subcutaneous or intramuscular only |
| Epitalon acetate | Subcutaneous or intramuscular only, intermittent courses |
| Semax free base | Intranasal only |
| KPV acetate | Topical or oral only (no subcutaneous) |
Who This Covers — And Who It Doesn't
Covered: State-licensed 503A pharmacies, federal facilities, licensed physicians — with patient-specific prescriptions from a licensed prescriber.
Not covered: Research-use-only vendors, online peptide sellers without prescriptions, 503B outsourcing facilities (the policy does not extend to them), combination products, anything bought without a patient-specific prescription.
What This Means for Combination Products
BPC-157 and TB-500 are frequently sold together as the "Wolverine stack." Combined in one product, they fall explicitly outside this policy. A premixed vial containing both does not qualify regardless of which peptides it contains.
Salt and Form Specificity
BPC-157 acetate is named. BPC-157 arginate is not automatically covered — different salt, not included.
N-Acetyl Semax Amidate is a different compound from Semax free base. Not covered.
Oral formulations require documented human bioavailability evidence for the actual formulation — a capsule existing is not the same as having that evidence.
Who Opposed It
FDA staff recommended against adding the seven peptides reviewed at the July 2026 Pharmacy Compounding Advisory Committee to the 503A Bulks List, citing safety and efficacy concerns. The committee voted to recommend several of them anyway; advisory votes are non-binding. The Partnership for Safe Medicines filed a citizen petition asking FDA to block compounding of these peptides. HHS has said it may revisit the policy if a safety signal or product-quality issue emerges.
The Evidence Baseline
The human evidence for BPC-157 is approximately 30 participants across three low-quality studies (as reported in an October 2026 systematic review, cited secondhand here), with "very low" certainty on the GRADE scale — the floor of the evidence quality framework used by clinicians worldwide. The policy created a conditional pharmacy pathway. It did not create new evidence.
How to Comment
Comments are open at regulations.gov, docket HHS-OASH-2026-0496, through approximately November 13, 2026.
Evidence limitation note: This post is based on the Federal Register notice (Doc. 2026-22192) and legal analyses by Foley & Lardner and Frier Levitt; the conditions are paraphrased, not quoted. The evidence-base figure is a secondary citation. Interpretation of conditions is editorial judgment, not legal advice. Readers with compliance questions should consult qualified legal counsel.
Sources
- Federal Register Doc. 2026-22192, published October 30, 2026. federalregister.gov
- Docket HHS-OASH-2026-0496. regulations.gov
- Foley & Lardner, "Peptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides," October 30, 2026.
- Frier Levitt, "HHS Peptide Compounding Enforcement Discretion Policy," October 2026.
- RAPS, "FDA advisory committee backs two controversial peptides," July 2026.
Published by PeptidesGPT, which offers a paid membership. PeptidesGPT is an educational platform; this post contains no product or purchase recommendations and does not constitute legal or medical advice. Consult a licensed healthcare provider for individualized medical guidance.
Keep reading with The Peptides Brief
One email a week on what the evidence actually says. No dosing, no hype.